OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
WATNYSE68

WATERS CORP /DE/

Advanced Medical Equipment & TechnologyVerified

Waters Corporation maintains a strong liquidity position with $587.83 million in cash and equivalents, but its net cash is negative after subtracting total debt of $947.45 million. The company's liquidity is assessed as medium, with a current ratio of 1.73, indicating it can cover its short-term liabilities with its current assets. The debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure, with total liabilities of $2.52 billion compared to total equity of $2.56 billion. In terms of profitability, Waters Corporation demonstrates a return on equity (ROE) of 25.09% and a return on assets (ROA) of 12.66%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of $802.59 million and net income of $642.63 million for FY2025 reflect a healthy margin, although these figures should be compared to the industry median to fully assess performance. Waters Corporation's revenue is primarily derived from the sale of analytical instruments, consumables, and service plans. The company operates through two segments: Waters and TA Instruments (TA). The Waters segment focuses on HPLC, UPLC, and MS systems, while the TA segment offers thermal analysis, rheometry, and calorimetry instruments. The company's geographic exposure is not explicitly detailed in the provided data, but its global operations suggest a diversified revenue base. The company's growth trajectory is supported by its consistent increase in annual service revenues and the development of advanced software-based products. Waters Corporation's recent acquisition of Halo Labs for $35.815 million and the subsequent reduction of its credit facility by $200 million to $1.8 billion indicate strategic financial management and expansion efforts. The company's operating cash flow of $652.56 million further supports its ability to fund operations and growth initiatives. Waters Corporation faces several risk factors, including global economic conditions, foreign currency fluctuations, and competition in the analytical instrument industry. The company's liquidity risk is moderate, with a current ratio of 1.73, but its net cash is negative after subtracting total debt. The risk of dilution is also moderate, with the company having a history of issuing shares and the potential for future offerings. The company's credit risk is not explicitly detailed, but its debt-to-equity ratio of 0.37 suggests a relatively low level of leverage. Recent events include the acquisition of Halo Labs and the amendment of the company's credit facility. The acquisition of Halo Labs for $35.815 million, with a net cash consideration of $35.053 million, is expected to have an immaterial effect on the company's consolidated results. The company also reduced its credit facility by $200 million to $1.8 billion, indicating a strategic move to manage its debt levels.

30-day price · WAT+25.57 (+8.4%)
Low$287.19High$357.45Close$329.22As of15 May, 00:00 UTC
Profile
CompanyWATERS CORP /DE/
ExchangeNYSE
TickerWAT
CIK0001000697
SICLaboratory Analytical Instruments
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Waters Corporation designs, manufactures, sells, and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS) systems, along with thermal analysis instruments and software for life sciences and diagnostics.

Classification. Waters is classified in the Healthcare economic sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

Waters Corporation maintains a strong liquidity position with $587.83 million in cash and equivalents, but its net cash is negative after subtracting total debt of $947.45 million. The company's liquidity is assessed as medium, with a current ratio of 1.73, indicating it can cover its short-term liabilities with its current assets. The debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure, with total liabilities of $2.52 billion compared to total equity of $2.56 billion. In terms of profitability, Waters Corporation demonstrates a return on equity (ROE) of 25.09% and a return on assets (ROA) of 12.66%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of $802.59 million and net income of $642.63 million for FY2025 reflect a healthy margin, although these figures should be compared to the industry median to fully assess performance. Waters Corporation's revenue is primarily derived from the sale of analytical instruments, consumables, and service plans. The company operates through two segments: Waters and TA Instruments (TA). The Waters segment focuses on HPLC, UPLC, and MS systems, while the TA segment offers thermal analysis, rheometry, and calorimetry instruments. The company's geographic exposure is not explicitly detailed in the provided data, but its global operations suggest a diversified revenue base. The company's growth trajectory is supported by its consistent increase in annual service revenues and the development of advanced software-based products. Waters Corporation's recent acquisition of Halo Labs for $35.815 million and the subsequent reduction of its credit facility by $200 million to $1.8 billion indicate strategic financial management and expansion efforts. The company's operating cash flow of $652.56 million further supports its ability to fund operations and growth initiatives. Waters Corporation faces several risk factors, including global economic conditions, foreign currency fluctuations, and competition in the analytical instrument industry. The company's liquidity risk is moderate, with a current ratio of 1.73, but its net cash is negative after subtracting total debt. The risk of dilution is also moderate, with the company having a history of issuing shares and the potential for future offerings. The company's credit risk is not explicitly detailed, but its debt-to-equity ratio of 0.37 suggests a relatively low level of leverage. Recent events include the acquisition of Halo Labs and the amendment of the company's credit facility. The acquisition of Halo Labs for $35.815 million, with a net cash consideration of $35.053 million, is expected to have an immaterial effect on the company's consolidated results. The company also reduced its credit facility by $200 million to $1.8 billion, indicating a strategic move to manage its debt levels.
Key takeaways
  • Waters Corporation maintains a strong liquidity position with $587.83 million in cash and equivalents, but its net cash is negative after subtracting total debt of $947.45 million.
  • The company's profitability is robust, with a return on equity (ROE) of 25.09% and a return on assets (ROA) of 12.66%.
  • Waters Corporation's revenue is primarily derived from the sale of analytical instruments, consumables, and service plans, with operations through two segments: Waters and TA Instruments (TA).
  • The company's growth trajectory is supported by its consistent increase in annual service revenues and the development of advanced software-based products.
  • Waters Corporation faces several risk factors, including global economic conditions, foreign currency fluctuations, and competition in the analytical instrument industry.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$3.17B
Gross profit
Operating income$802.6M
Net income$642.6M
R&D$195.7M
SG&A
D&A
SBC$54.1M
Operating cash flow$652.6M
CapEx
Free cash flow
Total assets$5.08B
Total liabilities$2.52B
Total equity$2.56B
Cash & equivalents$587.8M
Long-term debt$947.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$3.17B$802.6M$642.6M
FY2025$799.9M$192.1M
FY2025$771.3M$188.2M
FY2025$661.7M$151.7M
FY2024$2.96B$826.4M$637.8M
PeriodGross %Op %Net %FCF %
FY2025
FY2025
FY2025
FY2025
FY2024
PeriodAssetsEquityCashDebt
FY2025$5.08B$2.56B$587.8M
FY2025
FY2025
FY2025
FY2024$4.55B$1.83B$324.4M
PeriodOCFCapExFCFSBC
FY2025$652.6M$54.1M
FY2025
FY2025
FY2025
FY2024$762.1M$44.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$2.23B$532.1M$417.4M
Q2 2025$1.43B$340.0M$268.5M
Q3 2025
Q1 2025$661.7M$151.7M$121.4M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$4.86B$2.33B$459.1M
Q2 2025$4.72B$2.16B$367.2M
Q3 2025$2.16B
Q1 2025$4.59B$1.96B$382.9M
PeriodOCFCapExFCFSBC
Q3 2025$488.0M$39.6M
Q2 2025$300.7M$26.0M
Q3 2025
Q1 2025$259.6M$12.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$663.0M
Net cash-$358.7M
Current ratio1.7
Debt/Equity0.4
ROA12.7%
ROE25.1%
Cash conversion1.0%
CapEx/Revenue
SBC/Revenue1.7%
Asset intensity0.1
Dilution ratio0.3%
Risk assessment
Dilution riskMedium
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
MetricWATActivity
Op margin25.4%19.4% medp25 17.8% · p75 22.0%top quartile
Net margin20.3%17.7% medp25 16.4% · p75 19.0%top quartile
Gross margin73.5% medp25 71.3% · p75 75.8%
R&D / revenue6.2%6.2% medp25 4.7% · p75 12.0%above median
CapEx / revenue4.3% medp25 3.9% · p75 4.3%
Debt / equity37.0%41.5% medp25 29.2% · p75 51.3%below median
Observations
IR observations
Mean price target395.61 USD
Median price target400.00 USD
High price target480.00 USD
Low price target330.00 USD
Mean recommendation2.16 (1=strong buy, 5=strong sell)
Strong-buy count7.00
Buy count7.00
Hold count11.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate14.38 USD
Last actual EPS13.13 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
SEC filingstype companyfacts · CIK 0001000697 · 518 us-gaap concepts
2026-05-01 07:17 UTC#1d655437
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 07:19 UTCJob: e7a9097f